The Positioning of Ceftobiprole in Staphylococcus aureus Bacteremia
- PMID: 38466267
- DOI: 10.1093/cid/ciae123
The Positioning of Ceftobiprole in Staphylococcus aureus Bacteremia
Conflict of interest statement
Potential conflicts of interest. F. J. M. N. reports investigation grants from Advanz Pharma; payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing, or educational events from Advanz, Angelini, Correvio, MSD, Novartis, Pfizer, Gilead Sciences, ViiV Healthcare, and GSK; support for attending meetings and/or travel from Pfizer and MSD; and participation on advisory boards for Advanz and AstraZeneca. O. B. D. reports an investigation grant from Advanz. A. E. G. reports payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing, or educational events from Pfizer, Gilead Sciences, Advanz, MSD, Shionogi, and Menarini; and support for attending meetings and/or travel from Pfizer and Gilead Sciences. L. M. R. reports payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing, or educational events for Pfizer, Advanz, Angelini, MSD, and Menarini; and support for attending meetings and/or travel from Pfizer and Angelini. M. R. O. S. reports payment or honoraria for presentations in educational events for Pfizer, MSD, Gilead Sciences, GSK and Menarini; support for attending a medical congress from Angelini; and participation in an advisory board for Advanz. M. S. L. reports payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing, or educational events from Advanz, Angelini, Gilead, Janssen, Menarini, MSD, Pfizer, Shionogi, and Takeda; and support for attending meetings and/or travel from Pfizer, Gilead, and Takeda. M. E. M. reports payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing, or educational events from from Advanz, Gilead Sciences, and ViiV. C. H.-T. reports payment for expert testimony from Gilead, Janssen, Angelini, Shionogi, MSD, ViiV, and Bristol-Myers Squibb (BMS); support for attending meetings and/or travel from Gilead, Janssen, Angelini, Shionogi, MSD, ViiV, and BMS; and participation on a data and safety monitoring board or advisory board for Gilead, Janssen, Advanz, Angelini, Shionogi, MSD, ViiV, and BMS. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Comment on
-
The Positioning of Ceftobiprole in the Treatment of Staphylococcus aureus Bacteremia.Clin Infect Dis. 2024 Dec 17;79(6):1539-1540. doi: 10.1093/cid/ciae126. Clin Infect Dis. 2024. PMID: 38466317 No abstract available.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources